Adrenoceptors, Uncoupling Proteins, and Energy Expenditure
They conducted a meta-analysis of 11 large-scale clinical trials of GLP-1 receptor agonists involving a total of 85,373 people
Conclusions Together, once-weekly 2.4 mg semaglutide reduced all-cause mortality by 19%, CV deaths by 15%, and non-CV deaths by 23% among non-diabetic obese or overweight patients with CV disease
Other options may be worth considering for people who: Want a comprehensive in-person evaluation before starting GLP-1 treatment
These side effects typically resolved on their own and were most common during or just after dose increases
In addition, USA TODAYs review revealed at least 110 plaintiffs across both the federal and state lawsuits allege the drugs caused sudden blindness or severe vision changes, and at least one plaintiff says shes developed a serious neurological condition called Wernicke's encephalopathy that causes mental confusion, double vision and poor coordination